| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2008 | US20080014169 Compositions for Topical Enzymatic Debridement |
| 01/17/2008 | US20080014162 Method to treat skin in need of a calmative using at least one C-Glycoside derivative |
| 01/17/2008 | US20080014154 Novel Ethylene Copolymers, Compositions Containing Said Copolymers and Treatment Method |
| 01/17/2008 | US20080014152 Intranasal delivery of clenbuterol across the cribriform plate and into the brain |
| 01/17/2008 | US20080014148 Perturbed membrane-binding compounds and methods of using the same |
| 01/17/2008 | US20080014143 Methods and compositions for targeting gC1qR/p32 |
| 01/17/2008 | US20080014008 Applicator and Method for Applying Lanolin to a Sore Nipple |
| 01/17/2008 | US20080011293 Stable Xylometazoline and Oxymetazoline Solution |
| 01/17/2008 | DE4215677B4 Pharmazeutisches Mittel The pharmaceutical agent |
| 01/17/2008 | DE19845314B4 Procyanidinhaltiges Mittel zur Behandlung von erektiler Dysfunktion Procyanidinhaltiges agents for the treatment of erectile dysfunction |
| 01/17/2008 | DE112005003147T5 Verfahren Method |
| 01/17/2008 | DE102006032824A1 Substituierte Indazole Substituted indazoles |
| 01/17/2008 | DE102006032427A1 Use of composition comprising e.g. clozapine, quetiapine, olanzapine, benzyl- and/or phenylethyl alcohol, ethanol, ethereal oil, sweetener, and polyethylene glycol, for preparing an orally administering solution to treat schizophrenia |
| 01/17/2008 | DE102006032426A1 Use of a composition comprising e.g. clozapine and quetiapine; benzyl- and/or phenylethyl alcohol; propylene glycol; ethereal oil; and polyethylene glycol, for preparing an orally administering solution to treat schizophrenia |
| 01/17/2008 | DE102006032424A1 Behandlung von T-Zell-Malignomen Treatment of T-cell malignancies |
| 01/17/2008 | DE102006032414A1 Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Folsäure, Füllstoffen und Verdickern Cosmetic or dermatological preparations containing folic acid, fillers and thickeners |
| 01/17/2008 | DE102006032413A1 Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Folsäure und einem oder mehreren Polyolen Cosmetic or dermatological preparations containing folic acid and one or more polyols |
| 01/17/2008 | DE102006032412A1 Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Folsäure, flüchtigen und nichtflüchtigen Siliconen Cosmetic or dermatological preparations containing folic acid, volatile and non-volatile silicones |
| 01/17/2008 | DE102006032233A1 Use of a preparation containing eucalyptol/menthol for the production of medicament for combating and preventing virus infection and secondary bacterial infection |
| 01/17/2008 | DE102006032015A1 Zubereitungen zur Sebumreduktion mit einem Gehalt an Hydroxycitrat als wirksames Prinzip Preparations containing sebum reduction Hydroxycitrate as the active principle |
| 01/17/2008 | DE102006031813A1 Basische Acetophenone als Hemmstoffe von NO-Synthasen Basic acetophenones as inhibitors of NO synthases |
| 01/17/2008 | DE102006031224A1 New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases |
| 01/17/2008 | CA2690277A1 Pyrrolopyrimidines for pharmaceutical compositions |
| 01/17/2008 | CA2660855A1 Improved antibacterial antisense oligonucleotide and method |
| 01/17/2008 | CA2659814A1 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof |
| 01/17/2008 | CA2659666A1 Improvements relating to pharmaceutical compositions |
| 01/17/2008 | CA2659590A1 Irreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof |
| 01/17/2008 | CA2659392A1 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| 01/17/2008 | CA2659382A1 Pharmaceutical suspensions comprising phenylephrine and method of preparation |
| 01/17/2008 | CA2659121A1 Therapeutic compounds |
| 01/17/2008 | CA2659095A1 Fatty acid pharmaceutical foam |
| 01/17/2008 | CA2658417A1 Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
| 01/17/2008 | CA2658256A1 New 5-thioxylopyranose derivatives |
| 01/17/2008 | CA2658232A1 Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders |
| 01/17/2008 | CA2658223A1 Benzopyranopyrazoles |
| 01/17/2008 | CA2658222A1 Methods and compositions for increasing the efficiency of therapeutic antibodies using .gamma. .delta. t cell activators |
| 01/17/2008 | CA2658170A1 Controlled-release formulations |
| 01/17/2008 | CA2658146A1 Crystalline nemorubicin hydrochloride |
| 01/17/2008 | CA2658097A1 Pentadienamide derivatives |
| 01/17/2008 | CA2658069A1 Medicagenic acid saponin and uses thereof |
| 01/17/2008 | CA2657902A1 Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound |
| 01/17/2008 | CA2657816A1 Tetrahydrofuro [3, 2 -b] pyrr0l-3-ones as cathepsin k inhibitors |
| 01/17/2008 | CA2657771A1 Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| 01/17/2008 | CA2657748A1 Pharmaceutical and nutraceutical products comprising vitamin k2 |
| 01/17/2008 | CA2657719A1 Cyclopentane derivatives as antiglaucoma agents |
| 01/17/2008 | CA2657660A1 Substituted pyrazoles as ghrelin receptor antagonists |
| 01/17/2008 | CA2657651A1 Antiviral agents |
| 01/17/2008 | CA2657625A1 Therapeutic compounds |
| 01/17/2008 | CA2657623A1 Bridged diazepan orexin receptor antagonists |
| 01/17/2008 | CA2657611A1 Enhanced stability phenylephrine liquid compositions |
| 01/17/2008 | CA2657601A1 Substituted indazoles |
| 01/17/2008 | CA2657592A1 Adhesive patch containing fentanyl or a pharmaceutically acceptable salt thereof |
| 01/17/2008 | CA2657586A1 Preparation of pharmaceutical formulations |
| 01/17/2008 | CA2657582A1 Preparation of pharmaceutical compositions |
| 01/17/2008 | CA2657581A1 Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
| 01/17/2008 | CA2657552A1 Substituted diazepan orexin receptor antagonists |
| 01/17/2008 | CA2657548A1 Processes for preparing pharmaceutical compositions |
| 01/17/2008 | CA2657541A1 Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate |
| 01/17/2008 | CA2657535A1 Process for preparing diaminophenothiazinium compounds |
| 01/17/2008 | CA2657533A1 Drug delivery polymer with hydrochloride salt of clindamycin |
| 01/17/2008 | CA2657516A1 6,9-disubstituted purine derivatives and their use for treating skin |
| 01/17/2008 | CA2657421A1 A method for the production of fentanyl-based anesthetics for their oral transmucosal administration in a candy-like dosage form |
| 01/17/2008 | CA2657409A1 Nanoparticulate formulations of modafinil |
| 01/17/2008 | CA2657381A1 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhibitors |
| 01/17/2008 | CA2657379A1 Nanoparticulate sorafenib formulations |
| 01/17/2008 | CA2657375A1 Combination methods of treating cancer |
| 01/17/2008 | CA2657369A1 Short-acting benzodiazepine salts and their polymorphic forms |
| 01/17/2008 | CA2657350A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| 01/17/2008 | CA2657347A1 Short-acting benzodiazepine salts and their polymorphic forms |
| 01/17/2008 | CA2657336A1 Substituted isoxalines, pharmaceutical compositions containing same, methods of preparing same, and uses of same |
| 01/17/2008 | CA2657335A1 Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them |
| 01/17/2008 | CA2657332A1 Transdermal formulations of synthetic cannabinoids and nano colloidal silica |
| 01/17/2008 | CA2657327A1 Fused heterocyclic derivatives and methods of use |
| 01/17/2008 | CA2657300A1 Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| 01/17/2008 | CA2657275A1 Use of tylvalosin as antiviral agent |
| 01/17/2008 | CA2657256A1 Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing cognitive and physical performance |
| 01/17/2008 | CA2657227A1 Pyrimidine derivatives as alk-5 inhibitors |
| 01/17/2008 | CA2657151A1 Isoindoline derivatives for the treatment of arrhythmias |
| 01/17/2008 | CA2657117A1 Crystals of benzoxadiazole derivative |
| 01/17/2008 | CA2657078A1 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
| 01/17/2008 | CA2657069A1 4-piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| 01/17/2008 | CA2657062A1 Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 01/17/2008 | CA2657045A1 Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
| 01/17/2008 | CA2657043A1 Use of flibanserin for the treatment of sexual disorders in females |
| 01/17/2008 | CA2657027A1 Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| 01/17/2008 | CA2657006A1 Benzyl amines, a process for their production and their use as anti-inflammatory agents |
| 01/17/2008 | CA2656836A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 01/17/2008 | CA2656786A1 Fatty acid desaturases and uses thereof |
| 01/17/2008 | CA2656767A1 Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide |
| 01/17/2008 | CA2656579A1 Novel tyrosinase inhibitors, their process of preparation and their use in human medicine and in cosmetics |
| 01/17/2008 | CA2656456A1 Combination of adapalene and benzoyl peroxide for treating acne lesions |
| 01/17/2008 | CA2656451A1 Composition comprising a retinoid and benzoyl peroxide |
| 01/17/2008 | CA2656312A1 Zilpaterol enantiomer compositions and methods of making and using such compositions |
| 01/17/2008 | CA2656233A1 Improvements relating to pharmaceutical compositions |
| 01/17/2008 | CA2656229A1 Improvements relating to biocidal compositions |
| 01/17/2008 | CA2656223A1 Improvements relating to anti-parasitic compositions |
| 01/17/2008 | CA2656012A1 Purine derivatives as a2a agonists |
| 01/17/2008 | CA2655750A1 2-arylindole derivatives as mpges-1 inhibitors |
| 01/17/2008 | CA2655499A1 Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies |
| 01/17/2008 | CA2655202A1 Glucocorticoid receptor modulator and methods of use |